Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)

NCT01514201 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01514201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01514201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2012
Completion date
March 28, 2018
Enrollment
66 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, brain stem glioma, childhood mixed glioma, fibrillary astrocytoma, giant cell glioblastoma, glioblastoma, gliosarcoma, untreated childhood anaplastic astrocytoma, untreated childhood brain stem glioma, untreated childhood fibrillary astrocytoma, untreated childhood giant cell glioblastoma, untreated childhood glioblastoma, untreated childhood gliosarcoma